Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Cisapride fallout? Canada to gain access to largest adverse-event database

Barbara Sibbald
CMAJ October 01, 2002 167 (7) 790;
Barbara Sibbald
CMAJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Canada will soon have access to 350 000 adverse event reports annually through the world's largest repository of such data.

Figure

Figure. Vanessa Young: fallout from her death still being felt Photo by: Terrence Young

Health Canada's acting director general, Dr. Chris Turner, says an agreement providing access is slated to be signed with the US Food and Drug Administration this fall. The database, which includes information from Europe, should be accessible by early 2003. Negotiations began 4 years ago.

Canada's small population makes it difficult to assess the risk a new drug may pose (see CMAJ 2001;165[10]:1293). The larger database will provide Health Canada with more accurate information so it can issue timely warnings and advisories, or withdraw a drug.

Creation of a database was 1 of 17 recommendations directed at Health Canada after a coroner's inquest into the death of 15-year-old Oakville, Ont., resident Vanessa Young. She died of a cardiac arrhythmia in March 2000 while taking cisapride (Prepulsid) to treat digestive problems. The drug, contraindicated for patients like Young, who had bulimia, was pulled from the Canadian market in August 2000.

Her father, Terrence, says the larger database might help, but complains that Health Canada's 36-page response to the inquest addresses little else. “Health Canada gets an A for rhetoric and an F for substance,” says Young. “The real question is, are we any safer? I would say No. There have been a couple of positive steps but not enough and not quickly enough.”

Turner says all initiatives outlined in Health Canada's response “were already in development [before the jury issued its recommendations]. If we hadn't been thinking of it already we couldn't have responded so quickly, so comprehensively.” He said the department is “seriously considering” the jury's recommendations. “We've been looking at many for a while, but many also take extensive work to bring about.”

One source for delay is the fact that many of the 17 recommendations require cooperation between government agencies and professional bodies. For example, the jury recommended that only standard Health Canada information be given to patients at pharmacies. “We can only act in partnership,” says Turner.

Health Canada has also concluded that mandatory reporting of adverse events, which was recommended by the jury, is no solution. It says it has had little impact on reporting rates in countries such as France and Sweden, and in some countries has lowered the quality of reporting. Turner says it is the culture of reporting that must change so that physicians and others feel freer to make reports.

Young says his greatest frustration concerns Health Canada's reluctance to take responsibility for producing warnings and other advisories, as the jury recommended. “Health Canada should just issue them, not negotiate with the drug companies over the wording.” But Turner says the Dear Healthcare Professional letters that provide these warnings are the manufacturers' responsibility.

Young disagrees, and calls for an independent drug-safety network. “We don't allow the airlines to investigate their own crashes,” he says. — Barbara Sibbald, CMAJ

PreviousNext
Back to top

In this issue

CMAJ
Vol. 167, Issue 7
1 Oct 2002
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cisapride fallout? Canada to gain access to largest adverse-event database
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cisapride fallout? Canada to gain access to largest adverse-event database
Barbara Sibbald
CMAJ Oct 2002, 167 (7) 790;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Cisapride fallout? Canada to gain access to largest adverse-event database
Barbara Sibbald
CMAJ Oct 2002, 167 (7) 790;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Emergent Patterns in the Regulation of Pharmaceuticals: Institutions andInterests in the United States, Canada, Britain, and France
  • Google Scholar

More in this TOC Section

  • Longer family medicine residency: Boon or bane to doctor supply?
  • The evolving picture of long COVID
  • When are shared decisions false choices?
Show more News

Similar Articles

Collections

  • Topics
    • Patient safety & quality improvement

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire